RESUMO
Exacerbação aguda de asma é uma condição frequente na criança e no adolescente e uma das causas mais comuns de procura aos pronto atendimentos e de internações. Pode ocorrer em pacientes que ainda não foram diagnosticados como asmáticos, e mesmo naqueles cujo controle da doença não se encontre adequado. Reconhecer a exacerbação e iniciar seu tratamento desde o domicílio até o adequado manejo inicial em ambiente hospitalar é fundamental para evitar sua evolução para complicações que coloquem o paciente em risco de vida. O tratamento compreende o reconhecimento e tratamento da hipoxemia, da obstrução e do processo inflamatório, além de fornecer orientações na alta hospitalar e encaminhamentos para continuidade do tratamento.
Acute exacerbation of asthma is a frequent condition in children and adolescents and one of the most common causes of seeking emergency care and hospitalization. It can occur in patients who have not yet been diagnosed with asthma, and even in those whose disease control is not adequate. Recognizing the exacerbation and starting its treatment from home until proper initial management in a hospital environment is essential to avoid its evolution to complications that put the patient at risk of life. Treatment comprises the recognition and treatment of hypoxemia, obstruction, and the inflammatory process, in addition to providing guidance at hospital discharge and referrals for continued treatment.
Assuntos
Humanos , Recém-Nascido , Lactente , Pré-Escolar , Criança , Adolescente , Asma , Sociedades Médicas , Terapêutica , Alergia e Imunologia , Pacientes , Pediatria , Encaminhamento e Consulta , Teofilina , Espasmo Brônquico , Epinefrina , Corticosteroides , Ipratrópio , Anestésicos Inalatórios , Serviços Médicos de Emergência , Agonistas de Receptores Adrenérgicos beta 2 , Ventilação não Invasiva , Aminofilina , Hospitalização , Ketamina , Sulfato de Magnésio , Hipóxia , AntibacterianosRESUMO
OBJECTIVES: Although the efficacy of the addition of ipratropium bromide (IB) to short-acting ß2-agonists (SABAs) for treating children with moderate to severe asthma exacerbations has been demonstrated, evidence of its cost-effectiveness is scarce. The aim of the present study was to evaluate the cost-effectiveness of treatment with a combination of SABAs and IB compared with SABAs alone for the treatment of children with moderate to severe asthma exacerbations. METHODS: To achieve the objectives of the study, a decision-analysis model was adapted. Effectiveness parameters were obtained from a systematic review of the literature with meta-analysis. Cost data were obtained from hospital bills and from the national manual of drug prices in Colombia. The study was carried out from the perspective of the national healthcare system in Colombia. The main outcome of the model was avoidance of hospital admission. RESULTS: In children with moderate to severe asthma exacerbations, the base-case analysis showed that compared to SABAs alone, treatment with a combination of SABAs and IB was associated with lower overall treatment costs (US$126.24 vs. US$170.69 mean cost per patient) and a higher probability of hospital admission avoided (0.7999 vs. 0.7100), thus leading to dominance. For children with severe asthma exacerbations, these values were US$132.99 versus US$170.69 and 0.7883 versus 0.7100, respectively. CONCLUSIONS: In Colombia, when compared to therapy with SABAs alone, therapy with a combination of SABAs and IB for treating pediatric patients with moderate to severe asthma exacerbations involves a lower probability of hospital admission at lower treatment costs.
Assuntos
Asma , Ipratrópio , Administração por Inalação , Asma/tratamento farmacológico , Broncodilatadores/uso terapêutico , Criança , Análise Custo-Benefício , Quimioterapia Combinada , Hospitalização , Humanos , Ipratrópio/uso terapêuticoRESUMO
OBJECTIVE: Although valved spacers are the preferred method for administering metered-dose inhaler bronchodilators such as albuterol in pediatric acute asthma, their high cost and their lack of availability have limited their use, especially in low- and middle-income countries (LMICs). Because of this, it is a common practice to use home-made spacers, although a formal analysis evaluating their cost-effectiveness is lacking. Therefore, the objective of this study was to analyze the cost-effectiveness of home-made spacers compared to commercial valved spacers for delivering bronchodilator therapy in pediatric acute asthma. METHODS: A decision-analysis model was used to estimate health outcomes and costs of a simulated cohort of pediatric patients treated for acute asthma. Effectiveness parameters were obtained from a systematic review of the literature. Cost data were obtained from hospital bills and from the national manual of drug prices in Colombia. The study was carried out from the perspective of the national healthcare system in Colombia, a middle-income country (MIC). The main outcome of the model was avoidance of hospital admission. RESULTS: Base-case analysis showed that compared to commercial valved spacers, administering bronchodilators with home-made spacers results in lower overall treatment costs (US$126.75 vs. US$128.59 average cost per patient) without a significant difference in the probability of hospitalization avoided (0.8500 vs. 0.8500). CONCLUSIONS: The present study shows that in Colombia, an MIC, compared with commercial valved spacers, the use of home-made spacers for administering bronchodilator therapy is more cost-effective because it yields a similar probability of hospital admission at lower overall treatment costs.
Assuntos
Agonistas de Receptores Adrenérgicos beta 2/administração & dosagem , Asma/tratamento farmacológico , Broncodilatadores/administração & dosagem , Preços Hospitalares/estatística & dados numéricos , Inaladores Dosimetrados/economia , Administração por Inalação , Agonistas de Receptores Adrenérgicos beta 2/uso terapêutico , Broncodilatadores/uso terapêutico , Colômbia , Análise Custo-Benefício , Países em Desenvolvimento , Desenho de Equipamento , Humanos , Método de Monte Carlo , Revisões Sistemáticas como AssuntoRESUMO
BACKGROUND: Care variability for children with severe acute asthma has been well documented in high-income countries, yet data from low- and middle-income regions are lacking. We sought to characterize the magnitude of practice variability in the care of Latin American children to identify opportunities for standardization of care. METHODS: A cross-sectional study performed through a retrospective analysis of contemporaneously collected data of children with severe acute asthma admitted to a center contributing to the LARed Network registry between May 2017 and May 2019. Centers were grouped by geographic location: Atlantic (AT), South Pacific (SP), and North Central (NC). RESULTS: Among 434 children, most received care in hospitals in the AT group (54% [235/434]), followed by the NC (23% [101/434]) and SP (23% [98/434]) groups. The majority of children in the AT (92% [215/235]) and SP (91% [89/98]) groups received nebulized salbutamol/albuterol, while metered-dose inhalers were preferred in the NC group (72% [73/101]). There was a wide variation in the use of antibiotics: AT (57% [135/235]), SP (48% [47/98]), and NC (14% [14/101]). The same was true for ipratropium bromide: AT (67% [157/235]), SP (90% [88/98]), and NC (17% [17/101]), and aminophylline: AT (57% [135/235]), NC (5% [5/101]), and SP (0% [0/98]). High-flow nasal cannula was the preferred respiratory support modality in the AT (60% [141/235]) and NC (40% [40/101]) groups, while bilevel positive airway pressure (BiPAP) use was more common in the SP group (80% [78/98]). CONCLUSION: We identified significant variability in care for severe acute asthma. Our findings will help to inform the design of future studies, quality improvement initiatives, and development of practice guidelines within Latin America.
Assuntos
Asma/terapia , Adolescente , Albuterol/uso terapêutico , Aminofilina/uso terapêutico , Antibacterianos/uso terapêutico , Broncodilatadores/uso terapêutico , Cânula , Criança , Pré-Escolar , Estudos Transversais , Feminino , Hospitalização , Humanos , Ipratrópio/uso terapêutico , Masculino , Inaladores Dosimetrados , Estudos RetrospectivosRESUMO
OBJECTIVES: The benefits of metered-dose inhalers with a spacer (MDI+S) have increasingly been recognized as an alternative method of albuterol administration for treating pediatric asthma exacerbations. The aim of this systematic review was to compare the response to albuterol delivered through nebulization (NEB) with albuterol delivered through MDI+S in pediatric patients with asthma exacerbations. METHODS: We conducted an electronic search in MEDLINE/PubMed, EMBASE, Ovid, and ClinicalTrials. To be included in the review, a study had to a randomized clinical trial comparing albuterol delivered via NEB versus MDI+S; and had to report the rate of hospital admission (primary outcome), or any of the following secondary outcomes: oxygen arterial saturation, heart rate (HR), respiratory rate (RR), the pulmonary index score (PIS), adverse effects, and need for additional treatment. RESULTS: Fifteen studies (n = 2057) met inclusion criteria. No significant differences were found between the two albuterol delivery methods in terms of hospital admission (relative risk, 0.89; 95% confidence interval [CI], 0.55-1.46; I2 = 32%; p = .65). There was a significant reduction in the PIS score (mean difference [MD], -0.63; 95% CI, -0.91 to -0.35; I2 = 0%; p < .00001), and a significantly smaller increase in HR (better; MD -6.47; 95% CI, -11.69 to -1.25; I2 = 0%; p = .02) when albuterol was delivered through MDI+S than when it was delivered through NEB. CONCLUSIONS: This review, an update of a previously-published meta-analysis, showed a significant reduction in the PIS and a significantly smaller increase in HR when albuterol was delivered through MDI+S than when it was delivered through NEB.
Assuntos
Albuterol/administração & dosagem , Asma/tratamento farmacológico , Broncodilatadores/administração & dosagem , Nebulizadores e Vaporizadores , Sons Respiratórios/efeitos dos fármacos , Doença Aguda , Administração por Inalação , Criança , Progressão da Doença , Humanos , Ensaios Clínicos Controlados Aleatórios como AssuntoRESUMO
International guidelines have recommended the use of inhaled beta-2 agonists and systemic corticosteroids (SCs) as the first-line treatment for acute asthma. OBJECTIVE: To evaluate the evidence for the efficacy of inhaled corticosteroids (ICSs) in addition to SCs compared to SCs alone in children with acute asthma in the emergency department (ED) or during hospitalization. DATA SOURCES: Five electronic databases were searched. STUDY SELECTION: All randomized clinical trials that compared ICS (via nebulizer or metered dose inhaler) plus SC (oral or parenteral) with placebo (or standard care) plus SC were included without language restriction. DATA EXTRACTION: Two reviewers independently reviewed all the studies. The primary outcomes were hospital admission and hospital length of stay (LOS), and secondary outcomes were readmissions during follow-up, ED-LOS, lung function, asthma clinical score, oxygen saturation, and heart and respiratory rates. RESULTS: Nine studies (n = 1473) met the inclusion criteria. In all the studies, the ICS was budesonide. Compared to SC alone, adding budesonide to SC did not affect hospitalization rate, but decreased hospital LOS by more than 1 day (MD = -29.08 hours [-39.9 to -18.3]; I2 = 0%, P = < .00001). Moreover, adding budesonide significantly improved the acute asthma severity score among patients at ED. CONCLUSIONS: Compared to SC alone, adding budesonide to SC does not affect the hospitalization rate, but decreases the LOS and improves the acute asthma score in children in an ED setting.
Assuntos
Corticosteroides/administração & dosagem , Antiasmáticos/administração & dosagem , Asma/tratamento farmacológico , Doença Aguda , Administração por Inalação , Administração Oral , Criança , Quimioterapia Combinada , Hospitalização , Humanos , Nebulizadores e Vaporizadores , Ensaios Clínicos Controlados Aleatórios como AssuntoRESUMO
OBJECTIVES: Although a short course (ie, 3 to 5 days) of orally administered prednisolone is a common and widely accepted practice among clinicians for administering systemic corticosteroids in pediatric acute asthma, oral dexamethasone for 1 to 2 days is an attractive alternative to prednisolone due to its better palatability and compliance. However, a cost-effectiveness analysis regarding the use of dexamethasone compared to prednisolone is not sufficient, especially in lower- and middle-income countries. The objective of this study was to analyze the cost-effectiveness of prednisolone vs oral dexamethasone for treating pediatric asthma exacerbations. METHODS: Using a decision-analysis model, we analyzed the cost-effectiveness of prednisolone vs oral dexamethasone for treating acute pediatric asthma. Effectiveness parameters were derived from a systematic review of the published literature. Data for costs were acquired from hospital accounts and from an official national database, the national manual of drug prices in Colombia. The study was carried out from a Colombian third-party payer perspective. The principal outcome of the model was the avoidance of hospitalization. RESULTS: The base-case analysis showed that compared to dexamethasone, administering prednisolone was associated with lower overall treatment costs (US$93.97 vs US$104.91 mean cost per patient) without a significant difference in the probability of hospitalization avoided (.9108 vs .9108). CONCLUSIONS: The present study shows that in Colombia, a middle-income country, compared with oral dexamethasone, the use of prednisolone for treating acute pediatric asthma is cost-effective, yielding a similar probability of hospitalization at lesser overall costs.
Assuntos
Asma/economia , Dexametasona/economia , Glucocorticoides/economia , Prednisolona/economia , Administração Oral , Asma/tratamento farmacológico , Criança , Colômbia , Análise Custo-Benefício , Dexametasona/uso terapêutico , Glucocorticoides/uso terapêutico , Hospitalização , Humanos , Prednisolona/uso terapêuticoRESUMO
OBJECTIVES: Although the benefits of albuterol delivered via metered-dose inhalers with a spacer (MDI+S) have been increasingly recognized, the evidence regarding the cost-effectiveness of MDI+S compared to nebulization (NEB) is not sufficient, especially in less-affluent countries, where the clinical and economic burden of the disease is the greatest. The aim of the present study was to evaluate the cost-effectiveness of MDI+S vs NEB for delivering albuterol for the treatment of pediatric asthma exacerbations. METHODS: A decision-analysis model was developed to estimate the cost-effectiveness of MDI+S vs NEB for delivering albuterol for the treatment of pediatric asthma exacerbations. Effectiveness parameters were obtained from a systematic review of the literature. Cost data were obtained from hospital bills and from the national manual of drug prices in Colombia. The study was carried out from the perspective of the national healthcare system in Colombia, a middle-income country (MIC). The main outcome of the model was the avoidance of hospital admission. RESULTS: For the base-case analysis, the model showed that compared to NEB, using MDI+S for the delivery of albuterol was associated with lower total costs (US$96.68 vs US$121.41 average cost per patient) and a higher probability of hospital admission avoided (0.9219 vs 0.8900), thus leading to dominance. CONCLUSIONS: This study shows that in Colombia, an MIC, compared with NEB, the use of MDI+S for delivering albuterol for the treatment of pediatric asthma exacerbations is the preferred strategy because it is associated with a lower probability of hospital admission at lower total treatment costs.
Assuntos
Albuterol/administração & dosagem , Asma/tratamento farmacológico , Broncodilatadores/administração & dosagem , Broncodilatadores/economia , Inaladores Dosimetrados , Nebulizadores e Vaporizadores , Administração por Inalação , Albuterol/economia , Criança , Colômbia , Análise Custo-Benefício , Técnicas de Apoio para a Decisão , Hospitalização/estatística & dados numéricos , Humanos , Inaladores Dosimetrados/economiaRESUMO
Patients hospitalized for acute asthma treated with a pre-established algorithm could decrease hospital stay and critical bed (PICU) requirement. The objective of this article was to implement and evaluate the impact of a pre-established algorithm to treat children hospitalized for acute asthma. It is a cross-sectional and comparative study, with a prospective sample for convenience, of asthmatic children between 5 and 15 years admitted during 2017 without response to the first line of treatment in the emergency department. Patients with cardiorespiratory comorbidities and with direct admission to PICU were excluded. An algorithm was applied for 2 hours and its effectiveness was evaluated by a clinical score (PAS: English Pediatric Asthma Score). 55 patients were admitted, mean age 8.02 years, 41.8% female. The PAS decreased from 8 to 5 points at the end of the algorithm (p <0.001). When comparing the results obtained with the group treated the previous year, without algorithm application in 51 patients with similar demographic characteristics, a shorter hospitalization was observed (0.6 days versus 0.95 days (p <0.0368)). The algorithm in acute asthma unified treatment criteria and times in its application. A rapid decrease in clinical score and a shorter hospital stay were observed.
Los pacientes hospitalizados por asma agudo tratados con un algoritmo preestablecido, podrían disminuir la estancia hospitalaria y requerimiento de cama crítica (UCIP). El objetivo de este trabajo fue el de implementar y evaluar el impacto de un algoritmo preestablecido para tratar a niños hospitalizados por asma aguda. Es un estudio transversal y comparativo, con una muestra prospectiva por conveniencia, de niños asmáticos entre 5 y 15 años ingresados durante el 2017 sin respuesta a la primera línea de tratamiento en el servicio de urgencia. Se excluyeron pacientes con comorbilidades cardiorespiratorias y con ingreso directo a UCIP. Se aplicó un algoritmo durante 2 horas evaluando su efectividad mediante puntaje clínico (PAS, por su sigla en inglés Pediatric Asthma Score). Ingresaron 55 pacientes, edad media 8,02 años, 41,8% sexo femenino. El PAS disminuyó de 8 a 5 puntos al finalizar algoritmo (p <0,001). Al comparar los resultados obtenidos con el grupo tratado el año anterior, sin aplicación de algoritmo en 51 pacientes con similares características demográficas, se observó una hospitalización más breve (0,6 días versus 0,95 días (p < 0,0368)). El algoritmo en asma aguda unificó criterios de tratamiento y los tiempos en su aplicación. Se observó una rápida disminución del puntaje clínico y menor estancia hospitalaria.
Assuntos
Asma/terapia , Algoritmos , Criança Hospitalizada , Doença Aguda , Avaliação de Resultados em Cuidados de SaúdeRESUMO
INTRODUCCIÓN: Pocos estudios son concluyentes sobre la utilidad de la Oxigenoterapia por Cánula Nasal de Alto Flujo (CNAF) en pacientes con crisis asmática. OBJETIVO: Determinar la eficacia de la CNAF en niños mayores de 2 años con crisis asmática severa y moderada que no responde al tratamiento inicial. PACIENTES Y MÉTODO: Ensayo clínico randomizado controlado abierto de pacientes con exacerbación asmática en un Departamento de Emergencia Pediátrica. Se excluyó crisis mediadas por infecciones y comorbilidad. Los pacientes fueron aleatorizados: Grupo 1 CNAF (n: 32) y Grupo 2 Oxigenoterapia Convencional (n: 33). Ambos grupos recibieron el tratamiento farmacológico habitual. El primer punto de corte fue el descenso del PIS en más de 2 puntos a las 2 horas del tratamiento; los puntos secundarios: descenso del PIS a las 6 horas, tiempo de permanencia en la emergencia e ingreso a UCIP. RESULTADOS: Las características basales fueron similares en ambos grupos. La proporción de sujetos con disminución de más de dos puntos en el PIS a las 2 horas de tratamiento Grupo 1: 43,7% IC 95% (28-60) vs Grupo 2: 48,4%; IC 95% (32-64) p 0,447. La estadía media fue 24,8 ± 12,3 horas en el Grupo1 vs 24 ± 14,8 horas en el Grupo2; IC 95% (7,56-5,96) p 0,37. No encontramos diferencias del score y puntaje del esfuerzo respiratorio en mediciones cada 2 horas. Ningún paciente ingresó a cuidados intensivos. CONCLUSIONES: La incorporación de la CNAF al tratamiento de pacientes con crisis asmática no presentó beneficios clínicos ni disminuyó el tiempo de estadía en el DEP.
INTRODUCTION: There are few conclusive studies on the usefulness of High-Flow Nasal Cannula (HFNC) Oxygen Therapy in patients with asthmatic crises. OBJECTIVE: To determine the effectiveness of HFNC in chil dren older than 2 years of age that present severe and moderate asthmatic crises that do not respond to initial treatment. PATIENTS AND METHOD: Open controlled randomized clinical trial of patients with asthma exacerbation in the Pediatric Emergency Department. Infection- and comorbidity-media ted crises were excluded. Subjects were randomized as follows: Group 1 HFNC (n:32) and Group 2 Conventional Oxygen Therapy (n:33). Both groups received the usual pharmacological treatment. The first cut-off point was the decrease of more than 2 points of the PIS after 2 hours of treatment; secondary points were PIS decrease at 6 hours, stay time in the Emergency Room, and PICU admis sion. RESULTS: The patient's baseline characteristics were similar in both groups. The proportion of subjects with more than two points decrease in the PIS after two hours of treatment in Group 1 was 43.7% CI 95% (28-60) vs. Group 2 48.4%; CI 95% (32-64) p 0.447. The mean stay time was 24.8 ± 12.3 hours in Group 1 vs. 24 ± 14.8 hours in Group 2; CI 95% (7.56-5.96) p 0.37. We did not find differences in the respiratory effort score measurements every 2 hours. No patients were admitted to intensive care. CONCLUSIONS: The incorporation of HFNC oxygen therapy in the treatment of patients with asthmatic crises in the Pediatric Emergency Department did not show clinical benefits nor did it diminish the stay time.
Assuntos
Humanos , Masculino , Feminino , Pré-Escolar , Criança , Adolescente , Oxigênio/administração & dosagem , Estado Asmático/terapia , Cânula , Fatores de Tempo , Serviço Hospitalar de Emergência , Hospitais Pediátricos , Tempo de InternaçãoRESUMO
INTRODUCTION: In moderate-severe asthma exacerbation, salbutamol by inhaler (MDI) is superior to salbutamol delivered by nebulizer (NEB); however, to our knowledge, no studies in children with exclusively severe exacerbations were performed. OBJECTIVE: To compare the efficacy of salbutamol and ipratropium bromide by MDI versus by NEB in severe asthma exacerbations. METHODS: We performed a clinical trial enrolling 103 children (2-14 years of age) with severe asthma exacerbations (defined by the Pulmonary Score ≥ 7) seen at the emergency room in Asuncion, Paraguay. One group received salbutamol and ipratropium (two puff every 10 min for 2 h and then every 30 min for 2 h more) by MDI with a valved-holding chamber and mask along with oxygen by a cannula separately (MDI-SIB); and the other received nebulization with oxygen (NEB-SIB) of salbutamol and ipratropium (1 every 20 min for 2 h and then every 30 min for 2 h more). Primary outcome was the rate of hospitalization (Pulmonary Score ≥ 7) after 4 h and secondary outcome was oxygen saturation. RESULTS: Fifty two children received MDI-SIB and 51 NEB-SIB. After the 4th hour, children on MDI-SIB had significantly (P = 0.003) lower rate of hospital admission than on NEB-SIB (5.8% vs 27.5%, RR: 0.21 [0.06-0.69], respectively). Similarly, a significant improved clinical score after 60 min and increase in oxygen saturation after 90 min of treatment was observed in MDI-SIB versus NEB-SIB group (4.46 ± 0.7 vs 5.76 ± 0.65, P < 0.00001; and 90.5 ± 1.7 vs 88.43 1 ± 1, P < 0.00001, respectively). CONCLUSION: Even in severe asthma exacerbations administration of salbutamol and ipratropium by MDI with valved-holding chamber and mask along with oxygen by a cannula separately was more effective than by a nebulizer.
Assuntos
Albuterol/administração & dosagem , Asma/tratamento farmacológico , Broncodilatadores/administração & dosagem , Ipratrópio/administração & dosagem , Nebulizadores e Vaporizadores , Adolescente , Cânula , Criança , Pré-Escolar , Serviço Hospitalar de Emergência , Feminino , Hospitalização , Humanos , Espaçadores de Inalação , Masculino , Oxigênio/uso terapêuticoAssuntos
Asma , Prednisona , Criança , Dexametasona , Humanos , Controle de Qualidade , Projetos de PesquisaRESUMO
Introducción. El Mycoplasma pneumoniae puede estar implicado en la exacerbación refractaria del asma, Objetivo. Establecer la prevalencia de la infección por Mycoplasma pneumoniae en pacientes con exacerbación aguda del asma. Material y método. Se realizó un estudio prospectivo, transversal, observacional, caso-control, en pacientes mayores de 2 años y menores de 12. Se determinaron anticuerpos inmunoglobulina M (IgM) para M. pneumoniae por serología por técnica de ensayo por inmunoabsorción ligado a enzima (enzyme-linked immunosorbent assay; ELISA en sus siglas en inglés), utilizando el kit NovaLisa® NovaTec. Se consideró prueba positiva a valores > 11 NTU (NovaTec unidades). El análisis estadístico fue análisis de la varianza (analysis of variance; ANOVA, por sus siglas en inglés) y chi cuadrado con un nivel de significancia de p < 0,05. Resultados. Se estudiaron 180 niños, 130 correspondieron al grupo de niños asmáticos y 50, al grupo control. La IgM específica fue positiva en 60 pacientes, que correspondió al 46,15% de niños asmáticos (p < 0,001). La gravedad de la exacerbación estuvo relacionada directamente con los niveles de IgM (p < 0,001). La tasa de hospitalización fue de 75%, asociada de forma significativa con los niveles de IgM específica (p < 0,001). Conclusión. Nuestros datos sugieren que en los niños con asma aguda, tienen alta prevalencia (46%) de infección por Mycoplasma pneumoniae y estrecha relación entre la exacerbación aguda grave del asma y la infección por Mycoplasma pneumoniae. Estos resultados podrían tener implicaciones terapéuticas orientadas hacia la utilización de antibióticos específicos contra este microorganismo atípico.
Introduction. Mycoplasma pneumoniae may be involved in refractory asthma exacerbation. Objective. To determine the prevalence of Mycoplasma pneumoniae infection in patients with acute asthma exacerbation. Material and method. A prospective, crosssectional, observational, case-control study was carried out in patients older than 2 years old and younger than 12. Immunoglobulin M (IgM) antibodies were serologically determined for M. pneumoniae, using the NovaLisa® NovaTec kit for enzyme-linked immunosorbent assay (ELISA). Test results ≥ 11 NTU (NovaTec units) were regarded as positive. The statistical analysis was performed by means of the analysis of variance (ANOVA) and the χ² test, with a significance level of p < 0.05. Results. One hundred and eighty children were studied, of which 130 had asthma and 50 comprised the control group. Specific IgM was positive for 60 patients, that is 46.15% of the asthmatic children (p < 0.001). The severity of the exacerbation was directly related to IgM levels (p < 0.001). Hospitalization rate was 75%, and it was significantly associated to specific IgM levels (p < 0.001). Conclusion. Our data suggest that children with acute asthma show a high prevalence (46%) of Mycoplasma pneumoniae infection and that there is a close relation between severe acute asthma exacerbation and the presence of Mycoplasma pneumoniae infection. These findings might result in therapeutic implications centered in the use of specific antibiotics to fight this atypical organism.
Assuntos
Humanos , Masculino , Feminino , Pré-Escolar , Criança , Pneumonia por Mycoplasma/epidemiologia , Asma/fisiopatologia , Mycoplasma pneumoniae/isolamento & purificação , Pneumonia por Mycoplasma/complicações , Asma/microbiologia , Índice de Gravidade de Doença , Imunoglobulina M/imunologia , Ensaio de Imunoadsorção Enzimática/métodos , Estudos de Casos e Controles , Doença Aguda , Prevalência , Estudos Transversais , Estudos Prospectivos , Hospitalização/estatística & dados numéricosRESUMO
INTRODUCTION: Mycoplasma pneumoniae may be involved in refractory asthma exacerbation. OBJECTIVE: To determine the prevalence of Mycoplasma pneumoniae infection in patients with acute asthma exacerbation. Material and method. A prospective, crosssectional, observational, case-control study was carried out in patients older than 2 years old and younger than 12. Immunoglobulin M (IgM) antibodies were serologically determined for M. pneumoniae, using the NovaLisa® NovaTec kit for enzyme-linked immunosorbent assay (ELISA). Test results ≥ 11 NTU (NovaTec units) were regarded as positive. The statistical analysis was performed by means of the analysis of variance (ANOVA) and the χ² test, with a significance level of p < 0.05. RESULTS: One hundred and eighty children were studied, of which 130 had asthma and 50 comprised the control group. Specific IgM was positive for 60 patients, that is 46.15% of the asthmatic children (p < 0.001). The severity of the exacerbation was directly related to IgM levels (p < 0.001). Hospitalization rate was 75%, and it was significantly associated to specific IgM levels (p < 0.001). CONCLUSION: Our data suggest that children with acute asthma show a high prevalence (46%) of Mycoplasma pneumoniae infection and that there is a close relation between severe acute asthma exacerbation and the presence of Mycoplasma pneumoniae infection. These findings might result in therapeutic implications centered in the use of specific antibiotics to fight this atypical organism. Key words: acute asthma, exacerbation, Mycoplasma pneumoniae.
Introducción. El Mycoplasma pneumoniae puede estar implicado en la exacerbación refractaria del asma, Objetivo. Establecer la prevalencia de la infección por Mycoplasma pneumoniae en pacientes con exacerbación aguda del asma. Material y método. Se realizó un estudio prospectivo, transversal, observacional, casocontrol, en pacientes mayores de 2 años y menores de 12. Se determinaron anticuerpos inmunoglobulina M (IgM) para M. pneumoniae por serología por técnica de ensayo por inmunoabsorción ligado a enzima (enzymelinked immunosorbent assay; ELISA en sus siglas en inglés), utilizando el kit NovaLisa® NovaTec. Se consideró prueba positiva a valores ≥ 11 NTU (NovaTec unidades). El análisis estadístico fue análisis de la varianza (analysis of variance; ANOVA, por sus siglas en inglés) y chi cuadrado con un nivel de significancia de p < 0,05. Resultados. Se estudiaron 180 niños, 130 correspondieron al grupo de niños asmáticos y 50, al grupo control. La IgM específica fue positiva en 60 pacientes, que correspondió al 46,15% de niños asmáticos (p < 0,001). La gravedad de la exacerbación estuvo relacionada directamente con los niveles de IgM (p < 0,001). La tasa de hospitalización fue de 75%, asociada de forma significativa con los niveles de IgM específica (p < 0,001). Conclusión. Nuestros datos sugieren que en los niños con asma aguda, tienen alta prevalencia (46%) de infección por Mycoplasma pneumoniae y estrecha relación entre la exacerbación aguda grave del asma y la infección por Mycoplasma pneumoniae. Estos resultados podrían tener implicaciones terapéuticas orientadas hacia la utilización de antibióticos específicos contra este microorganismo atípico.
Assuntos
Asma/fisiopatologia , Mycoplasma pneumoniae/isolamento & purificação , Pneumonia por Mycoplasma/epidemiologia , Doença Aguda , Asma/microbiologia , Estudos de Casos e Controles , Criança , Pré-Escolar , Estudos Transversais , Ensaio de Imunoadsorção Enzimática/métodos , Feminino , Hospitalização/estatística & dados numéricos , Humanos , Imunoglobulina M/imunologia , Masculino , Pneumonia por Mycoplasma/complicações , Prevalência , Estudos Prospectivos , Índice de Gravidade de DoençaRESUMO
OBJECTIVES: To assess the efficacy of high-flow nasal cannula (HFNC) oxygen therapy and safety in children with asthma and moderate respiratory failure in the emergency department (ED). STUDY DESIGN: This was a prospective randomized pilot trial of children (aged 1-14 years) presenting to a tertiary academic pediatric ED with moderate-to-severe asthma exacerbations between September 2012 and December 2015. Patients with a pulmonary score (PS) ≥6 or oxygen saturation <94% with a face mask despite initial treatment (salbutamol/ipratropium bromide and corticosteroids) were randomized to HFNC or to conventional oxygen therapy. Pharmacologic treatment was at the discretion of attending physicians. The primary outcome was a decrease in PS ≥2 in the first 2 hours. Secondary outcomes included disposition, length of stay, and need for additional therapies. RESULTS: We randomly allocated 62 children to receive either HFNC (n = 30) or standard oxygen therapy (n = 32). Baseline patient characteristics were similar in the 2 groups. At 2 hours after the start of therapy, PS had decreased by ≥2 points in 16 patients in the HFNC group (53%) compared with 9 controls (28%) (P = .01). Between-group differences in disposition, length of stay, and need for additional therapies were not significant. No side effects were reported. CONCLUSION: HFNC appears to be superior to conventional oxygen therapy for reducing respiratory distress within the first 2 hours of treatment in children with moderate-to-severe asthma exacerbation refractory to first-line treatment. Further studies are needed to demonstrate its overall efficacy in the management of asthma and respiratory failure in the ED. TRIAL REGISTRATION: EudraCT: 2012-001771-36.
Assuntos
Asma/terapia , Oxigenoterapia/métodos , Insuficiência Respiratória/terapia , Antiasmáticos/uso terapêutico , Asma/complicações , Criança , Pré-Escolar , Serviço Hospitalar de Emergência/estatística & dados numéricos , Feminino , Humanos , Lactente , Tempo de Internação/estatística & dados numéricos , Masculino , Projetos Piloto , Estudos Prospectivos , Insuficiência Respiratória/complicações , Índice de Gravidade de Doença , Resultado do TratamentoRESUMO
Students presenting with varying degrees of respiratory symptoms and distress occur commonly in the school setting. It is important to develop a differential diagnosis for respiratory distress, to initiate stabilization of the student with life-threatening symptoms, and to triage these students to an appropriate level of care (back to the classroom, home with their guardian with follow up at their primary health care provider's office, or directly to the closest emergency department via Emergency Medical Services). This article describes the initial assessment and management of a student presenting with respiratory distress.
Assuntos
Crianças com Deficiência , Diagnóstico de Enfermagem , Síndrome do Desconforto Respiratório/enfermagem , Estudantes , Criança , Humanos , Guias de Prática Clínica como Assunto , Síndrome do Desconforto Respiratório/prevenção & controle , Serviços de Saúde Escolar , Serviços de Enfermagem EscolarRESUMO
OBJECTIVE: To determine whether 2 doses of dexamethasone is as effective as 5 days of prednisolone/prednisone therapy in improving symptoms and quality of life of children with asthma exacerbations admitted to the emergency department (ED). STUDY DESIGN: We conducted a randomized, noninferiority trial including patients aged 1-14 years who presented to the ED with acute asthma to compare the efficacy of 2 doses of dexamethasone (0.6 mg/kg/dose, experimental treatment) vs a 5-day course of prednisolone/prednisone (1.5 mg/kg/d, followed by 1 mg/kg/d on days 2-5, conventional treatment). Two follow-up telephone interviews were completed at 7 and 15 days. The primary outcome measures were the percentage of patients with asthma symptoms and quality of life at day 7. Secondary outcomes were unscheduled returns, admissions, adherence, and vomiting. RESULTS: During the study period, 710 children who met the inclusion criteria were invited to participate and 590 agreed. Primary outcome data were available in 557 patients. At day 7, experimental and conventional groups did not show differences related to persistence of symptoms (56.6%, 95% CI 50.6-62.6 vs 58.3%, 95% CI 52.3-64.2, respectively), quality of life score (80.0 vs 77.7, not significant [ns]), admission rate (23.9% vs 21.7%, ns), unscheduled ED return visits (4.6% vs 3.3%, ns), and vomiting (2.1% vs 4.4%, ns). Adherence was greater in the dexamethasone group (99.3% vs 96.0%, P < .05). CONCLUSION: Two doses of dexamethasone may be an effective alternative to a 5-day course of prednisone/prednisolone for asthma exacerbations, as measured by persistence of symptoms and quality of life at day 7. CLINICAL TRIAL REGISTRATION: clinicaltrialsregister.eu: 2013-003145-42.
Assuntos
Antiasmáticos/administração & dosagem , Asma/tratamento farmacológico , Dexametasona/administração & dosagem , Prednisolona/administração & dosagem , Prednisona/administração & dosagem , Doença Aguda , Administração Oral , Adolescente , Antiasmáticos/uso terapêutico , Criança , Pré-Escolar , Dexametasona/uso terapêutico , Progressão da Doença , Esquema de Medicação , Combinação de Medicamentos , Serviço Hospitalar de Emergência , Feminino , Seguimentos , Humanos , Lactente , Masculino , Adesão à Medicação/estatística & dados numéricos , Prednisolona/uso terapêutico , Prednisona/uso terapêutico , Estudos Prospectivos , Qualidade de Vida , Resultado do TratamentoRESUMO
Introducción: la terapia primaria en la crisis de asma aguda, incluye administración de oxígeno, uso de ß2-agonistas por vía inhalada y la administración de esteroides sistémicos. Las ventajas que se citan sobre el uso de los esteroides inhalados serían, su rápido inicio de acción y su buen perfil de seguridad, en contraposición a los esteroides sistémicos. Objetivo: evaluar la utilidad de los corticoides inhalados en el tratamiento de la crisis de asma aguda en niños mayores de 2 años. Métodos: se realizó un estudio prospectivo, transversal, experimental, aleatorizado, de eficacia clínica; la selección se realizó por medio de una tabla de números aleatorios, y se incluyeron tres grupos: el I recibió terapia estándar, el II la sustitución del esteroide sistémico por el inhalado y el III combinó a la terapia estándar el esteroide inhalado. El análisis estadístico se realizó por medio de ANOVA y chi cuadrado con una p< 0,05 como significativa. Resultados: se estudiaron 165 pacientes, los tres grupos de tratamiento mejoraron la escala de severidad inicial. Los pacientes que recibieron esteroides inhalados adicionados a la terapia estándar, tuvieron 73 por ciento de posibilidades de no ser hospitalizados, 27 por ciento de posibilidades de reducir el riesgo de hospitalizaciones y de cada 100 pacientes tratados con la combinación, se pudieran prevenir 8 hospitalizaciones(AU)
Assuntos
Humanos , Pré-Escolar , Criança , Corticosteroides/uso terapêutico , Estado Asmático/tratamento farmacológico , Budesonida/uso terapêutico , Estudos Transversais , Estudos ProspectivosRESUMO
Resumen ANTECEDENTES: 50% de las crisis asmáticas son desencadenadas por infecciones virales, su relación con parámetros clínicos no se ha descrito en los adultos. OBJETIVO: determinar la prevalencia de crisis asmáticas de acuerdo con el espectro viral y su asociación con características clínicas y mecánica respiratoria. MATERIAL Y MÉTODO: estudio clínico, prospectivo y observacional en el que se incluyeron pacientes con crisis asmática grave del 1 de diciembre de 2010 al 31 de diciembre de 2011. Se excluyeron los pacientes con sospecha de infección bacteriana. Se aplicó cuestionario de síntomas, se determinó panel viral por hisopado nasal, espirometría y estudios de laboratorio. Se obtuvo el consentimiento informado de los participantes. RESULTADOS: se incluyeron en el estudio 100 pacientes. La edad promedio fue de 39±14 años, IMC 27±4 kg/m2, escala de Borg 6.2±1.2, escala mMRC 2.6±0.6, tiempo de los síntomas 7±7 días, FEV1 de 42±14%, oximetría de pulso 88±3% y estancia de 4.5±1.7 días. El 47% de los pacientes tenía rinitis alérgica. Se aisló virus en 36% (rinovirus 15% y coronavirus 6%). Al comparar la causa viral vs no viral, se observó que los pacientes eran menores en el primer grupo (36±13 vs 43±17 años, p=0.014); no hubo diferencia entre grado de obstrucción y síntomas. A mayor severidad del asma hubo más aislamientos de virus. CONCLUSIÓN: las crisis asmáticas asociadas con virus respiratorios tienen comportamiento clínico similar al de las no asociadas. En los pacientes con menor edad y con comportamiento más grave se aíslan virus con más frecuencia.
Abstract BACKGROUND: 50% of asthma attacks are triggered by viral in fections; its relationship with clinical parameters has not been described in adults. OBJECTIVE: To determine the prevalence of asthma attacks according to viral spectrum and its association with clinical features and respiratory mechanics. MATERIAL AND METHOD: A clinical, prospective and observational study with patients with severe asthma attended from December 1st 2010 to December 31st 2011. We excluded patients with suspected bacterial infection. Symptom questionnaire was applied, it was determined by nasal swab viral panel, spirometry and laboratory studies. Informed consent was obtained. RESULTS: One hundred patients were included. Mean age was 39±14 years, BMI 27±4 kg/m2, Borg 6.2±1.2, mMRC 2.6±0.6, length of symptoms 7±7 days and FEV1 of 42±14%, pulse oximetry 88±3% and stay 4.5±1.7 days; 47% of patients had allergic rhinitis. Virus was isolated in 36% (15% rhinovirus and 6% coronavirus). Comparing the non-viral vs viral etiology, patients were younger (36±13 vs 43±17 years, p=0.014) there was no difference between the degree of obstruction and symptoms. A greater severity of asthma was related to more isolation. CONCLUSION: Asthma attacks associated with respiratory viruses have similar clinical behavior to not associated ones. In younger patients with more severe behavior virus are isolated more frequently.
RESUMO
La crisis de asma es el conjunto de síntomas, signos físicos y de laboratorio que apuntan a un aumento de la resistencia al flujo aéreo y como consecuencia la obstrucción bronquial. Es una causa frecuente de consulta y muchas veces la forma como se hace evidente la enfermedad en los pacientes y sus padres. En esta revisión entregamos algunas recomendaciones de cómo reconocer y responder rápidamente a esta situación. Los objetivos primarios al enfrentar una crisis son corregir la hipoxemia, obtener la bronco dilatación y disminuir el riesgo de recaídas. Para lograrlos, debe reconocer rápidamente la hipoxemia y aportar oxígenos suplementario, demostrar la obstrucción de la vía aérea (por clínica y/o laboratorio) y tratarla con broncodilatadores de acción rápida y corticoides sistémicos y una vez manejada la crisis dejar indicaciones suficientes para evitar que esto vuelva a ocurrir.
The asthma crisis is a group of symptoms, with physical and laboratory signs that show an increase in resistance to airflow because of the bronchial obstruction. It is a frequent cause of consultation and It is an often way that the disease becomes evident in patients and their parents. In this review we give some recommendations on how to recognize and have a quickly response to this situation. The primary objectives in facing a crisis are correcting hypoxemia, obtain broncho dilatation and decrease the risk of relapse. In order to achieve this, you should promptly recognize hypoxemia, provide supplemental oxygen, demonstrate airway obstruction (by clinic and / or laboratory) and treat it with rapid-acting bronchodilators and systemic corticosteroids and once the crisis is handled, leave sufficient indications to avoid this to happen again